AIMS/HYPOTHESIS: Enhanced plasma levels of NEFA have been shown to induce hepatic insulin resistance, which contributes to the development of type 2 diabetes. Indeed, sphingolipids can be formed via a de novo pathway from the saturated fatty acid palmitate and the amino acid serine. Besides ceramides, sphingosine 1-phosphate (S1P) has been identified as a major bioactive lipid mediator. Therefore, our aim was to investigate the generation and function of S1P in hepatic insulin resistance. METHODS: The incorporation of palmitate into sphingolipids was performed by rapid-resolution liquid chromatography-MS/MS in primary human and rat hepatocytes. The influence of S1P and the involvement of S1P receptors in hepatic insulin resistance was examined in human and rat hepatocytes, as well as in New Zealand obese (NZO) mice. RESULTS: Palmitate induced an impressive formation of extra- and intracellular S1P in rat and human hepatocytes. An elevation of hepatic S1P levels was observed in NZO mice fed a high-fat diet. Once generated, S1P was able, similarly to palmitate, to counteract insulin signalling. The inhibitory effect of S1P was abolished in the presence of the S1P2 receptor antagonist JTE-013 both in vitro and in vivo. In agreement with this, the immunomodulator FTY720-phosphate, which binds to all S1P receptors except S1P2, was not able to inhibit insulin signalling. CONCLUSIONS/ INTERPRETATION: These data indicate that palmitate is metabolised by hepatocytes to S1P, which acts via stimulation of the S1P2 receptor to impair insulin signalling. In particular, S1P2 inhibition could be considered as a novel therapeutic target for the treatment of insulin resistance.
AIMS/HYPOTHESIS: Enhanced plasma levels of NEFA have been shown to induce hepatic insulin resistance, which contributes to the development of type 2 diabetes. Indeed, sphingolipids can be formed via a de novo pathway from the saturated fatty acid palmitate and the amino acid serine. Besides ceramides, sphingosine 1-phosphate (S1P) has been identified as a major bioactive lipid mediator. Therefore, our aim was to investigate the generation and function of S1P in hepatic insulin resistance. METHODS: The incorporation of palmitate into sphingolipids was performed by rapid-resolution liquid chromatography-MS/MS in primary human and rat hepatocytes. The influence of S1P and the involvement of S1P receptors in hepatic insulin resistance was examined in human and rat hepatocytes, as well as in New Zealand obese (NZO) mice. RESULTS:Palmitate induced an impressive formation of extra- and intracellular S1P in rat and human hepatocytes. An elevation of hepatic S1P levels was observed in NZO mice fed a high-fat diet. Once generated, S1P was able, similarly to palmitate, to counteract insulin signalling. The inhibitory effect of S1P was abolished in the presence of the S1P2 receptor antagonist JTE-013 both in vitro and in vivo. In agreement with this, the immunomodulator FTY720-phosphate, which binds to all S1P receptors except S1P2, was not able to inhibit insulin signalling. CONCLUSIONS/ INTERPRETATION: These data indicate that palmitate is metabolised by hepatocytes to S1P, which acts via stimulation of the S1P2 receptor to impair insulin signalling. In particular, S1P2 inhibition could be considered as a novel therapeutic target for the treatment of insulin resistance.
Authors: Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin Journal: Nat Rev Drug Discov Date: 2010-10-29 Impact factor: 84.694
Authors: Daniel Knobeloch; Sabrina Ehnert; Lilianna Schyschka; Peter Büchler; Michael Schoenberg; Jörg Kleeff; Wolfgang E Thasler; Natascha C Nussler; Patricio Godoy; Jan Hengstler; Andreas K Nussler Journal: Methods Mol Biol Date: 2012
Authors: Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer Journal: Proc Natl Acad Sci U S A Date: 2003-03-10 Impact factor: 11.205
Authors: John R Ussher; Timothy R Koves; Virgilio J J Cadete; Liyan Zhang; Jagdip S Jaswal; Suzanne J Swyrd; David G Lopaschuk; Spencer D Proctor; Wendy Keung; Deborah M Muoio; Gary D Lopaschuk Journal: Diabetes Date: 2010-06-03 Impact factor: 9.461
Authors: Songhwa Choi; Justin M Snider; Chris P Cariello; Johana M Lambert; Andrea K Anderson; L Ashley Cowart; Ashley J Snider Journal: Prostaglandins Other Lipid Mediat Date: 2020-01-29 Impact factor: 3.072
Authors: Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel Journal: J Lipid Res Date: 2019-05-20 Impact factor: 5.922
Authors: Janin Henkel; Charles Dominic Coleman; Anne Schraplau; Korinna Jӧhrens; Daniela Weber; José Pedro Castro; Martin Hugo; Tim Julius Schulz; Stephanie Krämer; Annette Schürmann; Gerhard Paul Püschel Journal: Mol Med Date: 2017-03-21 Impact factor: 6.354
Authors: Tzu-Chieh Chen; Daniel I Benjamin; Taiyi Kuo; Rebecca A Lee; Mei-Lan Li; Darryl J Mar; Damian E Costello; Daniel K Nomura; Jen-Chywan Wang Journal: Sci Signal Date: 2017-07-25 Impact factor: 8.192